Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors.
Journal: Journal for immunotherapy of cancer
Published: July 21, 2025
Hypercalcemia of malignancy: Cancer treatment can be a cause as well.
Journal: Clinical nephrology
Published: June 07, 2024
Impact of personalized diabetes care on distress and treatment satisfaction in people with breast cancer.
Journal: Diabetic medicine : a journal of the British Diabetic Association
Published: July 20, 2023
Effects of aromatase inhibitor therapy on adiposity and cardiometabolic health in postmenopausal women: a controlled cohort extension study.
Journal: Endocrine connections
Published: March 05, 2023
Long-Term Changes in the Size of Pituitary Microadenomas.
Journal: Annals of internal medicine
Published: February 27, 2023
Dearth of ICD Codes for Complications of Immune Checkpoint Inhibitors Impedes Clinical Care and Research.
Journal: Journal of the Endocrine Society
Published: December 13, 2022
Effects of aromatase inhibitor therapy on visceral adipose tissue area and cardiometabolic health in postmenopausal women with early and locally advanced breast cancer.
Journal: Clinical endocrinology
Published: July 19, 2022
Bone Health and Denosumab Discontinuation in Oncology Populations.
Journal: The oncologist
Published: July 12, 2022
The Effects of Diabetes and Glycemic Control on Cancer Outcomes in Individuals With Metastatic Breast Cancer.
Journal: The Journal of clinical endocrinology and metabolism
Published: March 30, 2022
Patient-Centered Diabetes Care of Cancer Patients.
Journal: Current diabetes reports
Published: November 02, 2021
Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis.
Journal: Cancer immunology, immunotherapy : CII
Published: October 21, 2021
Factors leading to alpelisib discontinuation in patients with hormone receptor positive, human epidermal growth factor receptor-2 negative breast cancer.
Journal: Breast cancer research and treatment
Published: September 09, 2021
Last Updated: 09/26/2026